Up-regulation on cytochromes P450 in rat mediated by total alkaloid extract from Corydalis yanhusuo

BMC Complementary and Alternative Medicine

Chunhuan Jin²  Sheng Liang²  Yetao Ma²  Yiran Zhai²  Shan Feng²  Xin He¹  Jingjing Yan² 

[1] Tianjin State Key Laboratory of Modern Chinese Medicine, 312 Anshanxi Road, Tianjin 300193, Nankai District, China;School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, 312 Anshanxi Road, Tianjin 300193, Nankai District, China

关键词: Herb (drug)-drug interaction;    mRNA level;    Enzyme activity;    Histopathology;    Cytochromes P450;    Total alkaloid extract;   

Others  :  1086933
DOI  :  10.1186/1472-6882-14-306

 received in 2014-03-03, accepted in 2014-08-05,  发布年份 2014

【 摘 要 】

Background

Yanhusuo (Corydalis yanhusuo W.T. Wang; YHS), is a well-known traditional Chinese herbal medicine, has been used in China for treating pain including chest pain, epigastric pain, and dysmenorrhea. Its alkaloid ingredients including tetrahydropalmatine are reported to inhibit cytochromes P450 (CYPs) activity in vitro. The present study is aimed to assess the potential of total alkaloid extract (TAE) from YHS to effect the activity and mRNA levels of five cytochromes P450 (CYPs) in rat.

Methods

Rats were administered TAE from YHS (0, 6, 30, and 150 mg/kg, daily) for 14 days, alanine aminotransferase (ALT) levels in serum were assayed, and hematoxylin and eosin-stained sections of the liver were prepared for light microscopy. The effects of TAE on five CYPs activity and mRNA levels were quantitated by cocktail probe drugs using a rapid chromatography/tandem mass spectrometry (LC-MS/MS) method and reverse transcription-polymerase chain reaction (RT-PCR), respectively.

Results

In general, serum ALT levels showed no significant changes, and the histopathology appeared largely normal compared with that in the control rats. At 30 and 150 mg/kg TAE dosages, an increase in liver CYP2E1 and CYP3A1 enzyme activity were observed. Moreover, the mRNA levels of CYP2E1 and CYP3A1 in the rat liver, lung, and intestine were significantly up-regulated with TAE from 6 and 30 mg/kg, respectively. Furthermore, treatment with TAE (150 mg/kg) enhanced the activities and the mRNA levels of CYP1A2 and CYP2C11 in rats. However, the activity or mRNA level of CYP2D1 remained unchanged.

Conclusions

These results suggest that TAE-induced CYPs activity in the rat liver results from the elevated mRNA levels of CYPs. Co-administration of prescriptions containing YHS should consider a potential herb (drug)–drug interaction mediated by the induction of CYP2E1 and CYP3A1 enzymes.

【 授权许可】

   
2014 Yan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Liu YL, Yan LD, Zhou PL, Wu CF, Gong ZH: Levo-tetrahydropalmatine attenuates oxycodone-induced conditioned place preference in rats. Eur J Pharmacol 2009, 602:321-327.
• [2]He K, Gao JL, Zhao GS: Advances in studies on chemistry, pharmacology and quality control of Corydalis yanhusuo. Zhong Cao Yao 2007, 38:11-14.
• [3]Gao JL, He TC, Li YB, Wang YT: A traditional Chinese medicine formulation consisting of Rhizoma Corydalis and Rhizoma Curcumae exertssynergistic anti-tumor activity. Oncol Rep 2009, 22:1077-1083.
• [4]Choi JG, Kang SY, Kim JM, Roh DH, Yoon SY, Park JB, Lee JH, Kim HW: Antinociceptive effect of Cyperi rhizoma and Corydalis tuber extracts on neuropathic pain in rats. Korean J Physiol Pharmacol 2012, 16:387-392.
• [5]Chueh FY, Hsieh MT, Chen CF, Lin MT: DL-tetrahydropalmatine-produced hypotension and bradycardia in rats through the inhibition of central nervous dopaminergic mechanisms. Pharmacology 1995, 51:237-244.
• [6]Ling H, Wu L, Li L: Corydalis yanhusuo rhizoma extract reduces infarct size and improves heart function during myocardial ischemia/reperfusion by inhibiting apoptosis in rats. Phytother Res 2006, 20:448-453.
• [7]Chu H, Jin G, Friedman E, Zhen X: Recent development in studies of tetrahydroprotoberberines: mechanism in antinociception and drug addiction. Cell Mol Neurobiol 2008, 28:491-499.
• [8]Wang JB, Mantsch JR: L-tetrahydropalamatine: a potential new medication for the treatment of cocaine addiction. Future Med Chem 2012, 4:177-186.
• [9]Lai CK, Chan AY: Tetrahydropalmatine poisoning: diagnoses of nine adult overdoses based on toxicology screens by HPLC with diode-array detection and gas chromatography-mass spectrometry. Clin Chem 1999, 45:229-236.
• [10]Li L, Ye M, Bi K, Guo D: Liquid chromatography-tandem mass spectrometry for the identification of L-tetrahydropalmatine metabolites in Penicillium janthinellum and rats. Biomed Chromatogr 2006, 20:95-100.
• [11]Martignoni M, Groothuis GM, de Kanter R: Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006, 2:875-894.
• [12]Guo Y, Pope C, Cheng X, Zhou H, Klaassen CD: Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice. J Ethnopharmacol 2011, 138:111-118.
• [13]Zhao Y, Hellum BH, Liang A, Nilsen OG: The in vitro inhibition of human CYP1A2, CYP2D6 and CYP3A4 by tetrahydropalmatine, neferine and berberine. Phytother Res 2012, 26:277-283.
• [14]Sun SY, Wang YQ, Li LP, Wang L, Zeng S, Zhou H, Jiang HD: Stereoselective interaction between tetrahydropalmatine enantiomers and CYP enzymes in human liver microsomes. Chirality 2013, 25:43-47.
• [15]Vrba J, Vrublova E, Modriansky M, Ulrichova J: Protopine and allocryptopine increase mRNA levels of cytochromes P450 1A in human hepatocytes and HepG2 cells independently of AhR. Toxicol Lett 2011, 203:135-141.
• [16]Omiecinski CJ, Hassett C, Costa P: Developmental expression and in situ localization of the phenobarbital-inducible rat hepatic mRNAs for cytochromes CYP2B1, CYP2B2, CYP2C6, and CYP3A1. Mol Pharmacol 1990, 38(4):462-470.
• [17]Stiborová M, Stiborová-Rupertová M, Borek-Dohalská L, Wiessler M, Frei E: Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol 2003, 16:38-47.
• [18]He F, Bi HC, Xie ZY, Zuo Z, Li JK, Li X, Zhao LZ, Chen X, Huang M: Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids. Rapid Commun Mass Spectrom 2007, 21:635-643.
• [19]Chinese Pharmacopoeia Commission: Pharmacopoeia of the People’s Republic of China. Beijing: Chemical Industry Press; 2010:130-131. [Part I]
• [20]Zhao M, Li LP, Sun DL, Sun SY, Huang SD, Zeng S, Jiang HD: Stereoselective metabolism of tetrahydropalmatine enantiomers in rat liver microsomes. Chirality 2012, 24:368-373.
• [21]Paul LD, Springer D, Staack RF, Kraemer T, Maurer HH: Cytochrome P450 isoenzymes involved in rat liver microsomal metabolism of californine and protopine. Eur J Pharmacol 2004, 485:69-79.
• [22]Zuber R, Anzenbacherová E, Anzenbacher P: Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 2002, 6:189-198.
• [23]Guengerich FP: Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 1997, 106:161-182.
• [24]Arinc E, Arslan S, Bozcaarmutlu A, Adali O: Effects of diabetes on rabbit kidney and lung CYP2E1 and CYP2B4 expression and drug metabolism and potentiation of carcinogenic activity of N-nitrosodimethylamine in kidney and lung. Food Chem Toxicol 2007, 45:107-118.
• [25]Gonzalez FJ: The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. Drug Metab Dispos 2007, 35:1-8.
• [26]Takahashi S, Takahashi T, Mizobuchi S, Matsumi M, Morita K, Miyazaki M, Namba M, Akagi R, Hirakawa M: Increased cytotoxicity of carbon tetrachloride in a human hepatoma cell line overexpressing cytochrome P450 2E1. J Int Med Res 2002, 30:400-405.
• [27]McKillop IH, Schrum LW: Alcohol and liver cancer. Alcohol 2005, 35:195-203.
• [28]Neuwirth C, Mosesso P, Pepe G, Fiore M, Malfatti M, Turteltaub K, Dekant W, Mally A: Furan carcinogenicity: DNA binding and genotoxicity of furan in rats in vivo. Mol Nutr Food Res 2012, 56:1363-1374.
• [29]Picciotto A, Campo N, Brizzolara R, Giusto R, Guido G, Sinelli N, Lapertosa G, Celle G: Chronic hepatitis induced by Jin Bu Huan. J Hepatol 1998, 28:165-167.
• [30]Horowitz RS, Feldhaus K, Dart RC, Stermitz FR, Beck JJ: The clinical spectrum of Jin Bu Huan toxicity. Arch Intern Med 1996, 156:899-903.
• [31]Hu HF, Gao ZX, Cheng YY: Inhibition of CYP3A mRNA and protein expression, and enzymatic activity, by enrofloxacin in chickens. J Vet Pharmacol Ther 2010, 33:450-546.
• [32]Liu A, Yang J, Zhao X, Jiao X, Zhao W, Ma Q, Tang Z, Dai R: Induction of P450 3A1/2 and 2C6 by gemfibrozil in Sprague-Dawley rats. Pharmacol Rep 2011, 63:157-164.
• [33]Halvorson M, Greenway D, Eberhart D, Fitzgerald K, Parkinson A: Reconstitution of testosterone oxidation by purified rat cytochrome P450p (IIIA1). Arch Biochem Biophys 1990, 277(1):166-180.
• [34]Xu RA, Xu ZS, Ge RS: Effects of hydroxysafflor yellow A on the activity and mRNA expression of four CYP isozymes in rats. J Ethnopharmacol 2014, 151(3):1141-1146.
• [35]Debri K, Boobis AR, Davies DS, Edwards RJ: Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochem Pharmaco 1995, 50(12):2047-2056.
• [36]Qiu F, Wang G, Zhang R, Sun J, Jiang J, Ma Y: Effect of danshen extract on the activity of CYP3A4 in healthy volunteers. Br J Clin Pharmacol 2010, 69:656-662.
• [37]He N, Cai HB, Xie HG, Collins X, Edeki TI, Strom SC: Induction of cyp3a in primary cultures of human hepatocytes by ginkgolides a and B. Clin Exp Pharmacol Physiol 2007, 34:632-635.
• [38]Zhou SF, Wang B, Yang LP, Liu JP: Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010, 42:268-354.
• [39]Večeřa R, Zachařová A, Orolin J, Strojil J, Skottová N, Anzenbacher P: Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat. Biopharm Drug Dispos 2011, 32:482-487.
• [40]Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ: Apparent mechanism-based inhibition of human CYP2D6 in vitro byparoxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 2003, 31:289-293.